OTC醫藥品產業：主要5個新興國家市場的產業指南 是由出版商MarketLine在2010年11月所出版的。
這份英文市場調查報告書包含Pages: 192 價格從美金995起跳。
Abstract
Datamonitor' s OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide is
an essential resource for top-level data and analysis covering the OTC
Pharmaceuticals industry in each of the Top 5 Emerging markets (Brazil, China,
India, Mexico and South Africa). The report includes easily comparable data on
market value, volume, segmentation and market share, plus full five year
market forecasts. It examines future problems, innovations and potential
growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and
segmentation
* Provides textual analysis of the industry' s prospects, competitive
landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and
scorecards
* Compares data from Brazil, China, India, Mexico and South Africa, alongside
individual chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The Top 5 Emerging countries contributed $17658.8 million to the global OTC
Pharmaceuticals industry in 2009, with a CAGR of 7% between 2005 and 2009
China is the leading country among the Top 5 emerging nations, with market
revenues of $9,811. million in 2009.
The China is expected to lead the otc pharmaceuticals industry in the Top five
emerging nations, with a value of $13,449.9 in 2014
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market consists of the retail sale of traditional
medicines, cough and cold preparations (tablets, mixtures, lozenges, topical
remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals,
single vitamins, tonics, cod liver oil), indigestion preparations (tablets,
powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other
analgesics), and medicated skin products (anti-bacteria’s, acne
treatments, anti-fungal, disinfectants and other), topical OTC medicines
(anesthetic products, anti-itch products, antibiotic creams/gels), plasters &
bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze,
liquid bandages and other tape or bandage), first aid kits and other
(anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and
motion sickness).
Table of Contents
TABLE OF CONTENTS
ABOUT DATAMONITOR
INTRODUCTION
What is this report about?
Who is the target reader?
How to use this report
Definitions
TOP 5 EMERGING COUNTRIES OTC PHARMACEUTICALS OUTLOOK
OTC PHARMACEUTICALS IN SOUTH AFRICA
Market overview
Market value
Market segmentation I
Market share
Five forces analysis
Leading companies
Market distribution
Market Forecasts
Macroeconomic indicators
OTC PHARMACEUTICALS IN BRAZIL
Market overview
Market value
Market segmentation I
Market segmentation II
Market share
Five forces analysis
Leading companies
Market distribution
Market Forecasts
Macroeconomic indicators
OTC PHARMACEUTICALS IN CHINA
Market overview
Market value
Market segmentation I
Market segmentation II
Market share
Five forces analysis
Leading companies
Market distribution
Market Forecasts
Macroeconomic indicators
OTC PHARMACEUTICALS IN INDIA
Market overview
Market value
Market segmentation I
Market segmentation II
Market share
Five forces analysis
Leading companies
Market distribution
Market Forecasts
Macroeconomic indicators
OTC PHARMACEUTICALS IN MEXICO
Market overview
Market value
Market segmentation I
Market segmentation II
Market share
Five forces analysis
Leading companies
Market distribution
Market Forecasts
Macroeconomic indicators
APPENDIX
Data Research Methodology
LIST OF TABLES
Table 1: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m),
2005-14
Table 2: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m),
2005-09
Table 3: Top 5 emerging countries otc pharmaceuticals industry forecast,
revenue ($m), 2009-14
Table 4: South Africa otc pharmaceuticals market value: $ million,
2005-09
Table 5: South Africa otc pharmaceuticals market segmentation I:% share, by
value, 2009
Table 6: South Africa otc pharmaceuticals market share: % share, by value,
2009
Table 7: Pharma Natura (Pty) Ltd: key facts
Table 8: Weleda Group: key facts
Table 9: Johnson & Johnson: key facts
Table 10: Johnson & Johnson: key financials ($)
Table 11: Johnson & Johnson: key financial ratios
Table 12: South Africa otc pharmaceuticals market distribution: % share, by
value, 2009
Table 13: South Africa OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 14: South Africa size of population (million), 2005-09
Table 15: South Africa gdp (constant 2000 prices, $ billion), 2005-09
Table 16: South Africa gdp (current prices, $ billion), 2005-09
Table 17: South Africa inflation, 2005-09
Table 18: South Africa consumer price index (absolute), 2005-09
Table 19: South Africa exchange rate, 2005-09
Table 20: Brazil otc pharmaceuticals market value: $ million, 2005-09
Table 21: Brazil otc pharmaceuticals market segmentation I:% share, by value,
2009
Table 22: Brazil otc pharmaceuticals market segmentation II: % share, by
value, 2009
Table 23: Brazil otc pharmaceuticals market share: % share, by value, 2009
Table 24: Johnson & Johnson: key facts
Table 25: Johnson & Johnson: key financials ($)
Table 26: Johnson & Johnson: key financial ratios
Table 27: Sanofi-Aventis: key facts
Table 28: Sanofi-Aventis: key financials ($)
Table 29: Sanofi-Aventis: key financials (€)
Table 30: Sanofi-Aventis: key financial ratios
Table 31: Abbott Laboratories: key facts
Table 32: Abbott Laboratories: key financials ($)
Table 33: Abbott Laboratories: key financial ratios
Table 34: Brazil otc pharmaceuticals market distribution: % share, by value,
2009
Table 35: Brazil OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 36: Brazil size of population (million), 2005-09
Table 37: Brazil gdp (constant 2000 prices, $ billion), 2005-09
Table 38: Brazil gdp (current prices, $ billion), 2005-09
Table 39: Brazil inflation, 2005-09
Table 40: Brazil consumer price index (absolute), 2005-09
Table 41: Brazil exchange rate, 2005-09
Table 42: China otc pharmaceuticals market value: $ million, 2005-09
Table 43: China otc pharmaceuticals market segmentation I:% share, by value,
2009
Table 44: China otc pharmaceuticals market segmentation II: % share, by
value, 2009
Table 45: China otc pharmaceuticals market share: % share, by value, 2009
Table 46: Johnson & Johnson: key facts
Table 47: Johnson & Johnson: key financials ($)
Table 48: Johnson & Johnson: key financial ratios
Table 49: Novartis AG: key facts
Table 50: Novartis AG: key financials ($)
Table 51: Novartis AG: key financial ratios
Table 52: Chengdu Rosun Antiseptic Pharmaceutical Co., Ltd: key facts
Table 53: China otc pharmaceuticals market distribution: % share, by value,
2009
Table 54: China OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 55: China size of population (million), 2005-09
Table 56: China gdp (constant 2000 prices, $ billion), 2005-09
Table 57: China gdp (current prices, $ billion), 2005-09
Table 58: China inflation, 2005-09
Table 59: China consumer price index (absolute), 2005-09
Table 60: China exchange rate, 2005-09
Table 61: India otc pharmaceuticals market value: $ million, 2005-09
Table 62: India otc pharmaceuticals market segmentation I:% share, by value,
2009
Table 63: India otc pharmaceuticals market segmentation II: % share, by
value, 2009
Table 64: India otc pharmaceuticals market share: % share, by value, 2009
Table 65: Cipla Ltd: key facts
Table 66: Cipla Ltd: key financials ($)
Table 67: Cipla Ltd: key financials (Rs.)
Table 68: Cipla Ltd: key financial ratios
Table 69: Johnson & Johnson: key facts
Table 70: Johnson & Johnson: key financials ($)
Table 71: Johnson & Johnson: key financial ratios
Table 72: GlaxoSmithKline Plc: key facts
Table 73: GlaxoSmithKline Plc: key financials ($)
Table 74: GlaxoSmithKline Plc: key financials (£)
Table 75: GlaxoSmithKline Plc: key financial ratios
Table 76: India otc pharmaceuticals market distribution: % share, by value,
2009
Table 77: India OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 78: India size of population (million), 2005-09
Table 79: India gdp (constant 2000 prices, $ billion), 2005-09
Table 80: India gdp (current prices, $ billion), 2005-09
Table 81: India inflation, 2005-09
Table 82: India consumer price index (absolute), 2005-09
Table 83: India exchange rate, 2005-09
Table 84: Mexico otc pharmaceuticals market value: $ million, 2005-09
Table 85: Mexico otc pharmaceuticals market segmentation I:% share, by value,
2009
Table 86: Mexico otc pharmaceuticals market segmentation II: % share, by
value, 2009
Table 87: Mexico otc pharmaceuticals market share: % share, by value, 2009
Table 88: Bayer AG: key facts
Table 89: Bayer AG: key financials ($)
Table 90: Bayer AG: key financials (€)
Table 91: Bayer AG: key financial ratios
Table 92: Johnson & Johnson: key facts
Table 93: Johnson & Johnson: key financials ($)
Table 94: Johnson & Johnson: key financial ratios
Table 95: Boehringer Ingelheim GmbH: key facts
Table 96: Boehringer Ingelheim GmbH: key financials ($)
Table 97: Boehringer Ingelheim GmbH: key financials (€)
Table 98: Boehringer Ingelheim GmbH: key financial ratios
Table 99: Mexico otc pharmaceuticals market distribution: % share, by value,
2009
Table 100: Mexico OTC pharmaceuticals market value forecast: $ million,
2009-14
Table 101: Mexico size of population (million), 2005-09
Table 102: Mexico gdp (constant 2000 prices, $ billion), 2005-09
Table 103: Mexico gdp (current prices, $ billion), 2005-09
Table 104: Mexico inflation, 2005-09
Table 105: Mexico consumer price index (absolute), 2005-09
Table 106: Mexico exchange rate, 2005-09
LIST OF FIGURES
Figure 1: Top 5 emerging countries otc pharmaceuticals industry, revenue
($m), 2005-14
Figure 2: Top 5 emerging countries otc pharmaceuticals industry, revenue
($m), 2005-09
Figure 3: Top 5 emerging countries otc pharmaceuticals industry forecast,
revenue ($m), 2009-14
Figure 4: South Africa otc pharmaceuticals market value: $ million,
2005-09
Figure 5: South Africa otc pharmaceuticals market segmentation I:% share, by
value, 2009
Figure 6: South Africa otc pharmaceuticals market share: % share, by value,
2009
Figure 7: Forces driving competition in the otc pharmaceuticals market in
South Africa, 2009
Figure 8: Drivers of buyer power in the otc pharmaceuticals market in South
Africa, 2009
Figure 9: Drivers of supplier power in the otc pharmaceuticals market in
South Africa, 2009
Figure 10: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in South Africa, 2009
Figure 11: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in South Africa, 2009
Figure 12: Drivers of degree of rivalry in the otc pharmaceuticals market in
South Africa, 2009
Figure 13: Johnson & Johnson: revenues & profitability
Figure 14: Johnson & Johnson: assets & liabilities
Figure 15: South Africa otc pharmaceuticals market distribution: % share, by
value, 2009
Figure 16: South Africa OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 17: Brazil otc pharmaceuticals market value: $ million, 2005-09
Figure 18: Brazil otc pharmaceuticals market segmentation I:% share, by
value, 2009
Figure 19: Brazil otc pharmaceuticals market segmentation II: % share, by
value, 2009
Figure 20: Brazil otc pharmaceuticals market share: % share, by value, 2009
Figure 21: Forces driving competition in the otc pharmaceuticals market in
Brazil, 2009
Figure 22: Drivers of buyer power in the otc pharmaceuticals market in
Brazil, 2009
Figure 23: Drivers of supplier power in the otc pharmaceuticals market in
Brazil, 2009
Figure 24: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in Brazil, 2009
Figure 25: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in Brazil, 2009
Figure 26: Drivers of degree of rivalry in the otc pharmaceuticals market in
Brazil, 2009
Figure 27: Johnson & Johnson: revenues & profitability
Figure 28: Johnson & Johnson: assets & liabilities
Figure 29: Sanofi-Aventis: revenues & profitability
Figure 30: Sanofi-Aventis: assets & liabilities
Figure 31: Abbott Laboratories: revenues & profitability
Figure 32: Abbott Laboratories: assets & liabilities
Figure 33: Brazil otc pharmaceuticals market distribution: % share, by value,
2009
Figure 34: Brazil OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 35: China otc pharmaceuticals market value: $ million, 2005-09
Figure 36: China otc pharmaceuticals market segmentation I:% share, by value,
2009
Figure 37: China otc pharmaceuticals market segmentation II: % share, by
value, 2009
Figure 38: China otc pharmaceuticals market share: % share, by value, 2009
Figure 39: Forces driving competition in the otc pharmaceuticals market in
China, 2009
Figure 40: Drivers of buyer power in the otc pharmaceuticals market in China,
2009
Figure 41: Drivers of supplier power in the otc pharmaceuticals market in
China, 2009
Figure 42: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in China, 2009
Figure 43: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in China, 2009
Figure 44: Drivers of degree of rivalry in the otc pharmaceuticals market in
China, 2009
Figure 45: Johnson & Johnson: revenues & profitability
Figure 46: Johnson & Johnson: assets & liabilities
Figure 47: Novartis AG: revenues & profitability
Figure 48: Novartis AG: assets & liabilities
Figure 49: China otc pharmaceuticals market distribution: % share, by value,
2009
Figure 50: China OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 51: India otc pharmaceuticals market value: $ million, 2005-09
Figure 52: India otc pharmaceuticals market segmentation I:% share, by value,
2009
Figure 53: India otc pharmaceuticals market segmentation II: % share, by
value, 2009
Figure 54: India otc pharmaceuticals market share: % share, by value, 2009
Figure 55: Forces driving competition in the otc pharmaceuticals market in
India, 2009
Figure 56: Drivers of buyer power in the otc pharmaceuticals market in India,
2009
Figure 57: Drivers of supplier power in the otc pharmaceuticals market in
India, 2009
Figure 58: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in India, 2009
Figure 59: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in India, 2009
Figure 60: Drivers of degree of rivalry in the otc pharmaceuticals market in
India, 2009
Figure 61: Cipla Ltd: revenues & profitability
Figure 62: Cipla Ltd: assets & liabilities
Figure 63: Johnson & Johnson: revenues & profitability
Figure 64: Johnson & Johnson: assets & liabilities
Figure 65: GlaxoSmithKline Plc: revenues & profitability
Figure 66: GlaxoSmithKline Plc: assets & liabilities
Figure 67: India otc pharmaceuticals market distribution: % share, by value,
2009
Figure 68: India OTC pharmaceuticals market value forecast: $ million,
2009-14
Figure 69: Mexico otc pharmaceuticals market value: $ million, 2005-09
Figure 70: Mexico otc pharmaceuticals market segmentation I:% share, by
value, 2009
Figure 71: Mexico otc pharmaceuticals market segmentation II: % share, by
value, 2009
Figure 72: Mexico otc pharmaceuticals market share: % share, by value, 2009
Figure 73: Forces driving competition in the otc pharmaceuticals market in
Mexico, 2009
Figure 74: Drivers of buyer power in the otc pharmaceuticals market in
Mexico, 2009
Figure 75: Drivers of supplier power in the otc pharmaceuticals market in
Mexico, 2009
Figure 76: Factors influencing the likelihood of new entrants in the otc
pharmaceuticals market in Mexico, 2009
Figure 77: Factors influencing the threat of substitutes in the otc
pharmaceuticals market in Mexico, 2009
Figure 78: Drivers of degree of rivalry in the otc pharmaceuticals market in
Mexico, 2009
Figure 79: Bayer AG: revenues & profitability
Figure 80: Bayer AG: assets & liabilities
Figure 81: Johnson & Johnson: revenues & profitability
Figure 82: Johnson & Johnson: assets & liabilities
Figure 83: Boehringer Ingelheim GmbH: revenues & profitability
Figure 84: Boehringer Ingelheim GmbH: assets & liabilities
Figure 85: Mexico otc pharmaceuticals market distribution: % share, by value,
2009
Figure 86: Mexico OTC pharmaceuticals market value forecast: $ million,
2009-14
